Indazole Inhibitors Targeting LRRK2 Kinase for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for Parkinson's disease and other disorders associated with aberrant LRRK2 kinase activity are limited, with no disease-modifying therapies available to address the underlying neuropathological causes, and there is a need for effective LRRK2 inhibitors.
Innovation Solution
Development of indazole and azaindazole compounds that act as inhibitors of LRRK2, which can be administered to patients to treat neurodegenerative diseases by inhibiting the elevated expression or activity of LRRK2, thereby addressing the underlying cause of Parkinson's disease and other related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic strategies using supplemental dopaminergic medications are used, then symptom severity is reduced, but the underlying neuropathological cause is not addressed
Solution Approach 1:
The patent introduces LRRK2 inhibitors as intermediary compounds that block the pathological kinase activity of LRRK2, thereby addressing the underlying cause of Parkinson's disease rather than merely treating symptoms. These small molecule inhibitors act as mediators between the disease mechanism and therapeutic effect, providing disease-modifying treatment.
2Reliability
If LRRK2 inhibitors are developed to address underlying causes, then disease modification is achieved, but therapeutic options remain limited
Solution Approach 1:
The patent segments the LRRK2 protein into functional domains (kinase domain, ROC domain, COR domain, WD40 domain) and designs inhibitors that specifically target the kinase domain. This segmentation approach allows for selective inhibition of pathological activity while preserving other functions, and enables development of multiple compounds with different specificities.
Solution Approach 2:
The patent employs parameter changes by modifying chemical structures of indazole and azaindazole compounds to optimize their inhibitory activity against LRRK2. By adjusting molecular parameters such as substituent groups, ring structures, and stereochemistry, the patent generates a series of compounds with varying potency and selectivity profiles.
3Reliability
If the G2019S mutation in LRRK2 is targeted, then kinase activity enhancement is inhibited, but the complexity of LRRK2 multi-domain structure presents challenges
Solution Approach 1:
The patent extracts and isolates the kinase domain of LRRK2 as the primary target for inhibition, separating it from the complex multi-domain structure. By focusing on the kinase domain where the G2019S mutation occurs, the patent simplifies the therapeutic target while maintaining effectiveness against the pathological mechanism.
Data Source
AI summary
The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.